Orally bioavailable allosteric BiDAC degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer.
Currently Offered
CFT8919 is an orally bioavailable allosteric BiDAC degrader designed to be potent and selective against EGFR bearing the oncogenic L858R mutation. In preclinical studies the molecule is active in in vitro and in vivo models of L858R-driven non-small cell lung cancer and retains full activity against additional EGFR mutations that confer resistance to approved EGFR inhibitors, including L858R-C797S, L858R-T790M, and L858R-T790M-C797S.
The program addresses patients with EGFR L858R-mutant non-small cell lung cancer, who experience less durable responses to approved EGFR inhibitors and often develop secondary resistance. C4 Therapeutics exclusively licensed development and commercialization of CFT8919 in Greater China, including Hong Kong SAR, Macau SAR and Taiwan, to Betta Pharmaceuticals.
Adds products that compete with one of CFT8919’s direct competitors but not with CFT8919 itself. They are shaded, and Linked Through names the direct competitor each one competes with.
